TuHURA reports H1 2024 net loss $10.1M, cash $12.3M; merger with Kintara on track for Q4 2024

TuHURA Biosciences, Inc./NV

Net loss $10.1M for six months ended June 30, 2024; prior period loss $22.1M incl $16.2M IPR&D charge.
Cash $12.3M as of June 30, 2024, up from $3.7M at Dec 31, 2023; R&D expense $6.4M vs $4.0M YoY.
Convertible notes payable net $16.2M; derivative liability $2.0M; accumulated deficit $98.6M.
All-stock merger with Kintara expected to close Q4 2024; combined company to trade as HURA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.